Biomarkers for Neurodegenerative Disorders
Research focus: pathogenesis of Alzheimer's research, particularly search for new biomarkers for neurodegenerative diseases.
Biomarkers for neurodegenerative diseases are needed for early diagnosis, follow-up of the progression of the disease and monitoring of therapeutic responses.
Leader of the group is research director Sanna-Kaisa Herukka, MD, PhD, MSc.
We have a large biobank including blood and cerebrospinal fluid samples from over 2000 individuals including cognitively intact controls and subjects with neurodegenerative diseases (for example over 500 AD patients). These samples have been collected from our memory clinic and from subjects participating our longitudinal population-based studies.
We use different proteomic methods (immunoassays, 2D electrophoresis) for the analyses of blood, CSF and brain samples (in collaboration with Kuopio Brain Bank), and RNA macroarrays for the analyses of brain samples. We also use different tissue culture models for the functional studies.
Main Achievements and Services
In our clinical-pathological study we have shown that CSF amyloid-β42, Tau and phospho-Tau are markers for AD type pathology and can be used for prediction of AD in MCI subjects. Based on these studies we have standardised the measurements of CSF amyloid-β42, Tau and phospho-Tau and established a service laboratory that makes these tests available for clinicians and other interested parties. See link http://www.uef.fi/alzheimermarkkeritutkimukset.
– NADINE – https://www.fp7nadine.eu/
– Joint Program of Neurodegederative Diseases – BIOMARKAPD
– Quality Program of Alzheimer Association
Group members - UEF
Valtteri Julkunen Clinical Lecturer , School of Medicine, Institute of Clinical Medicine